TAMPA, FL--(Marketwire - January 12, 2010) - Stem Cell Therapy International, Inc. (OTCBB: SCII) ("AmStem Corporation") announced that Rick van den Toorn has been
appointed to the Company's Board of Directors effective January 22, 2010.
In this role he will become a valued board member by overseeing the
establishment of and providing oversight to several committees, including
the compensation and audit committees and he will evaluate and monitor the
Company's strategic operational plans.
David Stark, President and CEO of SCII, commented, "Mr. van den Toorn is a
strong addition to our Board. He is a seasoned executive with
international business experience and we are confident that his knowledge,
expertise and independent leadership will contribute significantly to our
Company, particularly during this exciting time as we finalize our merger
with Histostem and begin a phase of growth and change."
"I am excited to join SCII at this pivotal point in the Company's growth
trajectory," Rick van den Toorn stated. "As SCII transitions to the next
level of its development, I believe my career experience in international
business and finance will enable me to make a positive contribution towards
the Company's business development goals, such as increasing infrastructure
and the establishment of effective operating practices moving forward."
Mr. van den Toorn is an investor and advisor with a focus on U.S. based
small to mid-capitalization companies. He is a citizen of the Netherlands
and most recently worked for the Dutch Authority for the Financial Markets
where he was a senior member of the team responsible for the oversight of
audit firms. Before that, Mr. van den Toorn worked as a special consultant
to corporations and entities including The World Bank. Mr. van den Toorn
began his career with KPMG as an accountant and business consultant where
he became a partner in the firm and gained broad experience in many areas
such as risk management, accounting, and corporate governance. He holds a
B.A. degree in Economics from the HEAO in Alkmaar, The Netherlands and is
registered as a chartered accountant through NIVRA, the Dutch accounting
institute.
About Stem Cell Therapy International, Inc.
Stem Cell Therapy International, Inc. (OTCBB: SCII) is in the field of
regenerative medicine. SCII (soon to have its name changed to AmStem
Corporation) is a company devoted to the treatment of patients with stem
cell transplantation therapy as well as providing the supplies of
biological solutions containing new lines of stem cell products.
About AmStem International Corporation
AmStem is a new biotechnology company based in Northern California, in the
watershed of stem cell innovation fueled by President Obama's recent
announcement to lift Federal funding limitations for stem cell research.
AmStem provides biotherapeutic and cosmetic stem cell products, stem cell
collection and storage know-how, and access to nanotechnology vital to
cutting edge stem cell research. Its web site is under construction at
www.amsteminc.com.
About Histostem Co. Ltd.
Histostem was founded in Seoul, Korea in 2000, to date it has treated more
than 500 patients with stem cells and currently has approximately 50
full-time employees and several part-time employees. Histostem's
intellectual property portfolio consists of 6 patents that have been
granted and 5 patents pending. To its knowledge Histostem is one of the
very few stem cell companies in the world currently earning several million
dollars in income from its products and technology. A comprehensive list of
Histostem's achievements can be found at the company's website
http://www.histostem.co.kr (click on English version when entering the
site).
Forward-Looking Statements
Some of the statements included in this press release, particularly those
anticipating future clinical and business prospects for Stem Cell Therapy
International, Inc., may be forward-looking statements that involve a
number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in
the Private Securities Litigation Reform Act of 1995. Among the factors
that could cause our actual results to differ materially are the following:
our ability to obtain necessary capital, our ability to successfully
complete the merger, successfully complete clinical trials; our ability to
meet anticipated development timelines, our ability to establish global
market for the cord blood cells, clinical trial results, successfully
consummate future acquisitions, manufacturing capabilities or other
factors; and other risk factors identified from time to time in our reports
filed with the Securities and Exchange Commission. Any forward-looking
statements set forth in this press release speak only as of the date of
this press release. We do not intend to update any of these forward-looking
statements to reflect events or circumstances that occur after the date
hereof.
